Navigation Links
Sweet genes
Date:7/3/2014

Edmonton, July 3, 2014 A research team at the Faculty of Medicine & Dentistry at the University of Alberta have discovered a new way by which metabolism is linked to the regulation of DNA, the basis of our genetic code. The findings may have important implications for the understanding of many common diseases, including cancer.

The DNA wraps around specialized proteins called histones in the cell's nucleus. Normally, histones keep the DNA tightly packaged, preventing the expression of genes and the replication of DNA, which are required for cell growth and division. In order for these critical functions to take place, histones need to be modified with the attachment of an acetyl-group, donated by a critical molecule called acetyl-CoA. This attachment relaxes the DNA, allowing for DNA replication and gene expression. This mechanism is called "epigenetic regulation of DNA" and is important for normal functions (like the growth of an embryo or brain functions) or in common diseases like heart failure or cancer. Until now, how the nucleus generates acetyl-CoA for histone acetylation had remained elusive.

The research team, lead by postdoctoral fellow Gopinath Sutendra and professor Evangelos Michelakis in the Department of Medicine, discovered that an enzyme thought to reside only within mitochondria, called Pyruvate Dehydrogenase Complex (PDC), can actually find its way into the nucleus and do what it is designed to do in the mitochondria: generate acetyl-CoA. When in mitochondria, PDC uses the carbohydrates from our diet to generate acetyl-CoA for energy production. When in the nucleus, PDC can produce acetyl-CoA for histone acetylation.

"Although this jumping of an enzyme from one organelle into another in the cell is not unheard off, our results were quite surprising", Sutendra says. "We wanted to measure acetyl-CoA levels and PDC in the mitochondria because that's where we thought they were. But accidentally we had the nuclei isolated at the same time and we saw PDC in the nucleus. So we asked, 'what is PDC doing there?' And that started it all."

"We were surprised that, despite the recognized importance of histone acetylation in cell biology and medicine, and despite the efforts by many to develop drugs that regulate histone acetylation, the source of acetyl-CoA in the nucleus had remained unknown," Michelakis says. "Sometimes the answers to important biological questions are just next to you, waiting to be discovered," he adds.

The team found that the translocation of PDC into the nucleus made cancer cells grow faster, an observation that may lead to additional strategies in the war against cancer. Yet, because the findings relate to how our DNA is regulated in general, this work may have far broader implications for many physiologic or pathologic conditions where epigenetic regulation is critical. "We are very excited about this new pathway linking energy production (the process known as metabolism) with gene regulation," the researchers say.

The work is published in the July 3, 2014, issue of the journal Cell. Michelakis is particularly proud of the fact that this is the product of a team that is entirely based at the University of Alberta. Many young researchers in the Department of Medicine like Adam Kinnaird, Peter Dromparis and Roxane Paulin were critical members of the team that also included technicians (Trevor Stenson, Alois Haromy, Kyoko Hashimoto) and researchers from the NanoFAB facility (Nancy Zhang, Eric Flaim). The work was funded by the Canadian Institutes for Health Research and the Hecht Foundation (Vancouver, Canada).


'/>"/>

Contact: Ross Neitz
rneitz@ualberta.ca
780-492-5986
University of Alberta Faculty of Medicine & Dentistry
Source:Eurekalert

Related biology news :

1. Sweet sweet straw
2. The sweetest calculator in the world
3. The future of sweet cherry in Australia
4. Childrens preferences for sweeter and saltier tastes are linked to each other
5. Nectar: A sweet reward from plants to attract pollinators
6. UT Austin engineer converts yeast cells into sweet crude biofuel
7. Are sweetpotato weevils differentially attracted to certain colors?
8. The economically valuable sweet-gum trees: Taxonomy and 9 new combinations
9. Targeting cancers sweet tooth
10. The brain cannot be fooled by artificial sweeteners
11. Carbonation alters the minds perception of sweetness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Corporation (NASDAQ: VWR), the leading global independent provider of product ... its financial results for the fourth quarter and full year ... 4Q16 record quarterly net sales of $1.13 billion, up ... 4Q16 EMEA-APAC segment net sales increased ... net sales increased 2.5%, or down 0.9% on an organic ...
(Date:2/23/2017)... Feb. 23, 2017 /PRNewswire/ - The Fight Against Cancer ... Research (OICR) are pleased to report that Fusion Pharmaceuticals ... with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) ... groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as ... ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure ... at home or in healthcare facilities during periods of rest. A lightweight, non-invasive ...
Breaking Biology Technology: